Zymeworks Inc. (ZYME)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: countertrend limit - price 24.77 below SMA50 26.66 with MACD -0.48 < 0; a pullback bid into a live short-term downtrend, not a dip within an uptrend. No breakout stop qualifies either: no consolidation base (price below full MA stack, serial lower highs) and technicalScore 2 < 3 required for entry.
Company overview
Zymeworks Inc. is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for cancer treatment. Its lead candidates are zanidatamab, a bispecific antibody in Phase 1 and 2 trials, and ZW49, an antibody-drug conjugate in Phase 1 trials. The company collaborates with several major pharmaceutical firms and is headquartered in Vancouver, Canada.
Fundamental
fairZymeworks shows strong liquidity but remains unprofitable with high execution risk and negative DCF outputs.
Liquidity looks strong (8-K: $403.8M cash/marketable securities at 2026-03-31), but ZYME is still unprofitable with volatile, milestone-driven revenue and material clinical/partner risks disclosed in SEC filings. Fundamental score: 3/5.
Sentiment
fairMedia and retail sentiment are sparse, with limited coverage and engagement around recent earnings and price-target updates.
Near-term narrative is driven by post-Q2 results digestion (earnings, announced) and the still-unresolved Theravance acquisition process (ongoing_process, announced), with a modest bullish overlay from a recent price-target raise. Quantified media-sentiment delta is indeterminate (sentiment scanner returned 0 usable in-window items after a timeout); legal screen shows no regulator-confirmed investigations (only law-firm solicitation noise).
Technical
weakThe stock is below all key moving averages with a negative MACD, indicating a weak-bearish trend.
Weak-bearish, bounce-only chart (2/5): price 24.77 sits below every tracked moving average (SMA20 26.29, SMA50 26.66, SMA200 25.06, EMA9 25.53, EMA21 26.09, WMA9 25.39, WMA21 25.93, DEMA14 25.18, TEMA14 24.90) and below the 10-14 daily VWAP 24.85, after a five-session slide from 26.53 (10-07 close) to 24.77 with serial lower highs (26.34 -> 25.79 -> 25.60 -> 25.18). MACD -0.48/-0.30/-0.18 is negative and widening, RSI14 41.2 is weak; Williams %R -95.4 is the only washed-out bullish argument and ADX14 13.4 confirms no trend strength. Neither entry type qualifies: the pullback/oversold limit is countertrend (price < SMA50 with MACD < 0 - trend-alignment gate), and no breakout stop exists to buy (no consolidation base; score 2 < 3). Do Nothing.
You’re looking at 2026-10-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

